<DOC>
	<DOCNO>NCT00775528</DOCNO>
	<brief_summary>This study ass safety tolerability pancrelipase delay release capsule subject 6 year age Pancreatic Exocrine Insufficiency ( PEI ) due Cystic Fibrosis .</brief_summary>
	<brief_title>Study Investigating Delayed-Release Pancrelipase Patients With Pancreatic Exocrine Insufficiency Due Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Confirmed Cystic Fibrosis ( CF ) diagnosis two positive chloride sweat test gene analysis Current historical human fecal elastase &lt; 50µg/gstool Weight great 3.75 kg Age 1 month 6 year Currently receive treatment commercially available pancreatic enzyme product stable dose 3 month Clinically stable condition without evidence acute respiratory disease acute condition Ileus acute abdomen History fibrosing colonopathy , Celiac disease , gastrectomy , Crohn´s disease small bowel surgery minor resection due meconium ileus without result malabsorption syndrome History distal ileal obstruction syndrome within 6 month enrollment Use immunosuppressive drug Any type malignancy involve digestive tract last 5 year Known infection HIV</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Pancreatic Exocrine Insufficiency</keyword>
</DOC>